基因编辑技术在肿瘤治疗中的应用进展  

Applications of Gene Editing Technologies in Cancer Therapy

作　　者：熊祥宇 贝锦新[1] XIONG Xiangyu;BEI Jinxin(State Key Laboratory of Oncology in South China,Guangdong Provincial Clinical Research Center for Cancer,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]华南恶性肿瘤防治全国重点实验室,广东省恶性肿瘤临床医学研究中心,中山大学肿瘤防治中心,广州510060

出　　处：《中国细胞生物学学报》2023年第12期1746-1756,共11页Chinese Journal of Cell Biology

基　　金：国家自然科学基金(批准号:82261160657)资助的课题。

摘　　要：基于工程或细菌核酸酶的基因编辑技术的发展实现了在几乎所有真核细胞中直接靶向和修饰基因组序列的可能性。该文综述了三大基因编辑技术锌指核酸酶(zinc finger nucleases,ZFNs)、类转录激活因子效应核酸酶(transcription activator-like effector nucleases,TALENs)、规律间隔成簇短回文重复序列和相关蛋白(clustered regularly interspaced short palindromic repeat and CRISPR-associated proteins,CRISPR/Cas)的发展史以及它们在肿瘤治疗领域的应用进展,并探讨了基因编辑技术在临床上应用于肿瘤治疗所面临的挑战。The development of gene editing technologies,stemming from engineered or bacterial nucleases,has enabled precise targeting and modification of genomic sequences across a majority of eukaryotic cells.This review provides a comprehensive overview of the evolution and advancements of three paramount gene editing systems:ZFNs(zinc finger nucleases),TALENs(transcription activator-like effector nucleases),and CRISPR/Cas(clustered regularly interspaced short palindromic repeat and CRISPR-associated proteins).This discourse further elucidates their potential applications in cancer therapeutics and highlights the challenges encountered in integrating these gene editing modalities into clinical therapy practice.

关 键 词：基因编辑 ZFNs TALENs CRISPR/Cas 肿瘤治疗 

分 类 号：R73-36[医药卫生—肿瘤]